Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

110.00
+1.080.99%
Post-market: 110.000.00000.00%19:30 EDT
Volume:523.14K
Turnover:57.65M
Market Cap:7.57B
PE:-35.29
High:112.59
Open:109.38
Low:106.58
Close:108.92
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:1.08
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:73.54
PE(LYR):-35.37

Loading ...

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity

Simply Wall St.
·
Yesterday

Rhythm Pharma Files Form 3 for Chief Medical Officer Manher Joshi

Reuters
·
Aug 19

Rhythm Pharmaceuticals Appoints Manher “AJ” Joshi as Chief Medical Officer

Reuters
·
Aug 17

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

THOMSON REUTERS
·
Aug 17

Rhythm Pharma EVP, Head of International Yann Mazabraud Sells USD 6.61 Million in Common Shares

Reuters
·
Aug 15

UK MHRA Expands Rhythm’s Imcivree Authorization to Treat Acquired Hypothalamic Obesity

Reuters
·
Aug 11

Rhythm Pharmaceuticals: to Work Closely with UK's Nhs to Finalize Guidance for Coverage of Imcivree for Acquired Ho

THOMSON REUTERS
·
Aug 11

Rhythm Pharmaceuticals Announces Imcivree® (Setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity Due to Hypothalamic Injury or Impairment

THOMSON REUTERS
·
Aug 11

Rhythm Pharmaceuticals Price Target Raised to $146.00/Share from $145.00 by JP Morgan

Dow Jones
·
Aug 08

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data

Simply Wall St.
·
Aug 07

Rhythm Pharmaceuticals is Maintained at Market Outperform by Citizens

Dow Jones
·
Aug 05

RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating

MT Newswires Live
·
Aug 05

Immuneering Expects Cash Runway to Fund Operations into 2029

Reuters
·
Aug 05

Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens

TIPRANKS
·
Aug 05

Sweden's Xspray Posts Narrow Q2 Pretax Loss as Costs Fall

Reuters
·
Aug 05

Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows

Reuters
·
Aug 05

Travere Therapeutics Q2 Product Sales Rise on Filspari Demand

Reuters
·
Aug 05

Precigen Posts Quarterly Profit as Papzimeos Sales Surge

Reuters
·
Aug 05

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Reuters
·
Aug 05

Rigel Pharmaceuticals Q2 Revenue Rises on Strong Product Demand

Reuters
·
Aug 05